New insights into the pathogenesis and drug treatment of myelofibrosis
A Tefferi - Current opinion in hematology, 2006 - journals.lww.com
Current opinion in hematology, 2006•journals.lww.com
Recent advances in the pathogenesis of myelofibrosis with myeloid metaplasia are
expected to facilitate the development of molecularly targeted therapy. In the mean time,
current management strategies include observation, participation in experimental drug
therapy, and allogeneic stem cell transplantation for low-risk, intermediate-risk, and high-risk
disease, respectively.
expected to facilitate the development of molecularly targeted therapy. In the mean time,
current management strategies include observation, participation in experimental drug
therapy, and allogeneic stem cell transplantation for low-risk, intermediate-risk, and high-risk
disease, respectively.
Summary
Recent advances in the pathogenesis of myelofibrosis with myeloid metaplasia are expected to facilitate the development of molecularly targeted therapy. In the mean time, current management strategies include observation, participation in experimental drug therapy, and allogeneic stem cell transplantation for low-risk, intermediate-risk, and high-risk disease, respectively.
Lippincott Williams & Wilkins